These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16400301)

  • 1. Research update on Parkinson's disease and other movement disorders: highlights from the Eighteenth Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, October 3, 2004, Toronto, Ontario, Canada.
    Weiner WJ
    Rev Neurol Dis; 2005; 2(1):27-9. PubMed ID: 16400301
    [No Abstract]   [Full Text] [Related]  

  • 2. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    Neurology; 1998 Feb; 50(2):573-4. PubMed ID: 9484410
    [No Abstract]   [Full Text] [Related]  

  • 3. PET studies and physiopathology of motor fluctuations in Parkinson's disease.
    Linazasoro G; Leenders KL
    Brain; 2004 Aug; 127(Pt 8):E15; author reply E16. PubMed ID: 15277309
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's Disease in the UK and Germany.
    Barnett G; Williams AC
    J Med Econ; 2015 Nov; 18(11):858-9. PubMed ID: 26121159
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply: Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's Disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Nov; 18(11):860-2. PubMed ID: 26212480
    [No Abstract]   [Full Text] [Related]  

  • 6. The pragmatic use of apomorphine at the end of life.
    Dewhurst F; Lee M; Wood B
    Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Objective assessment in Parkinson's disease: optoelectronic movement and force analysis in clinical routine and research.
    Ingvarsson PE; Johnels B; Steg G; Olsson T
    Adv Neurol; 1999; 80():447-58. PubMed ID: 10410755
    [No Abstract]   [Full Text] [Related]  

  • 8. New treatment for people with Parkinson's.
    FDA Consum; 2004; 38(4):5. PubMed ID: 15346564
    [No Abstract]   [Full Text] [Related]  

  • 9. New drug helps Parkinson's "off" periods.
    Health News; 2004 Jul; 10(7):2. PubMed ID: 15239150
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug for "off" episodes of Parkinson's--effective but limited.
    Mayo Clin Health Lett; 2005 Jul; 23(7):4. PubMed ID: 16189845
    [No Abstract]   [Full Text] [Related]  

  • 11. [Current treatment strategies for Parkinson's disease].
    Südmeyer M; Wojtecki L; Schnitzler A
    Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract]   [Full Text] [Related]  

  • 13. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 14. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 15. Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
    Djamshidian A; Poewe W
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S9-S12. PubMed ID: 28012951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apomorphine hydrochloride for the treatment of Parkinson's disease.
    Unti E; Ceravolo R; Bonuccelli U
    Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004; 5(4):211-2. PubMed ID: 15230626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
    Obering CD; Chen JJ; Swope DM
    Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern therapy of Parkinson's disease.
    Ransmayr G; Künig G; Gerstenbrand F
    J Neural Transm Suppl; 1992; 38():129-40. PubMed ID: 1491245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.